13 Oct MagForce AG: MagForce USA, Inc. has Received FDA’s Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
Posted at 08:10h
in Client News